Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Cannbit, subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announce collaboration for the development of novel medical cannabis products
troyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from troyrecord.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
REHOVOT, Israel, Jan. 21, 2021 /PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn s & Colitis Congress® to be held from today January 21-24, 2021.
Prof. Yehuda Ringel, CSO of Biomica, will present
BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD on Saturday 23
rd January, 2021 at 2PM (EST).
The Crohn s & Colitis Congress is jointly organized by the American Crohn s & Colitis Foundation (CCFA) and the American Gastroenterological Association (AGA). The Congress connects IBD providers and researchers from around the world and will be held virtually this year.
Share this article
Share this article
REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference. The conference is being held on January 28-29, 2021, virtually.
Dr. Elran Haber, Biomica s Chief Executive Officer, is scheduled to speak on the European Microbiome Leaders Panel during the morning opening plenary session on January 28 at 9:00 am CET.
Biomica Logo
Evogene Logo
The panel discussion will address current strategies to take microbiome-based therapeutics to market; the role of partnerships in future therapeutic strategies; what public institutions and regulators can do to support the microbiome sector; what tools can be utilized to reveal causation and molecular mechanisms of microbiome-based t